

Vasko Kramer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4926288/publications.pdf>

Version: 2024-02-01

12
papers

241
citations

1307594

7
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

256
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-body biodistribution and radiation dosimetry of [¹⁸ F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders. <i>EJNMMI Research</i> , 2022, 12, 1.	2.5	8
2	Biodistribution and dosimetry of a single dose of albumin-binding ligand [¹⁷⁷ Lu]Lu-PSMA-ALB-56 in patients with mCRPC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 893-903.	6.4	36
3	FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?. <i>Cancers</i> , 2021, 13, 4946.	3.7	67
4	[¹⁸ F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2021, 46, 119-124.	1.3	5
5	Characterization of the serotonin 2A receptor selective PET tracer (R)-[¹⁸ F]MH.MZ in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 355-365.	6.4	6
6	Evaluation of [¹⁸ F]-N-Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies. <i>ACS Chemical Neuroscience</i> , 2020, 11, 427-435.	3.5	20
7	Pharmacokinetic evaluation of [¹⁸ F]PR04.MZ for PET/CT imaging and quantification of dopamine transporters in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1927-1937.	6.4	11
8	Image-Guided Development of Heterocyclic Sulfoxides as Ligands for Tau Neurofibrillary Tangles: From First-in-Man to Second-Generation Ligands. <i>ACS Omega</i> , 2018, 3, 7567-7579.	3.5	12
9	Imaging Nigrostriatal Dopaminergic Deficit in Holmes Tremor with ¹⁸ F-PR04.MZ-PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, 740-741.	1.3	9
10	Direct radiofluorination of [¹⁸ F]MH.MZ for 5-HT _{2A} receptor molecular imaging with PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 354-358.	1.0	6
11	¹⁸ F-Labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT _{2A} antagonists for molecular imaging. <i>Nuclear Medicine and Biology</i> , 2010, 37, 487-495.	0.6	23
12	Synthesis and in vitro affinities of various MDL 100907 derivatives as potential ¹⁸ F-radioligands for 5-HT _{2A} receptor imaging with PET. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2989-3002.	3.0	38